AMRX vs DD · P/E 44, rev $2.79B vs P/E 127, rev $12.39B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Dupont De Nemours Inc (DD) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Dupont De Nemours Inc (DD) is a specialty chemicals company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported DD revenue for 2024-12-31 was $12.39B. Net income was $738.0M. Revenue was up 2.6% from 2023-12-31 to 2024-12-31. DD currently screens at market cap $19.61B and trailing P/E 127.4.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. DD currently screens at market cap $19.61B and trailing P/E 127.4.
Not investment advice. Open the AMRX and DD stock pages for the full models.
Not investment advice.